Aveanna Healthcare (NASDAQ:AVAH - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, March 13th. Analysts expect the company to announce earnings of $0.00 per share and revenue of $499.61 million for the quarter. Parties that are interested in participating in the company's conference call can do so using this link.
NASDAQ AVAH opened at $4.03 on Thursday. The firm has a market cap of $778.70 million, a P/E ratio of -11.85 and a beta of 2.24. The stock's 50-day moving average is $4.62 and its 200-day moving average is $5.02. Aveanna Healthcare has a one year low of $2.11 and a one year high of $6.19.
Separately, Truist Financial dropped their price target on Aveanna Healthcare from $6.00 to $5.25 and set a "hold" rating on the stock in a research report on Monday, January 6th.
Get Our Latest Stock Analysis on AVAH
Aveanna Healthcare Holdings Inc, a diversified home care platform company, provides pediatric and adult healthcare services in the United States. Its patient-centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals or skilled nursing facilities.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Aveanna Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aveanna Healthcare wasn't on the list.
While Aveanna Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.